<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224405</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2010-019004-24</org_study_id>
    <nct_id>NCT01224405</nct_id>
  </id_info>
  <brief_title>Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy</brief_title>
  <acronym>PON-PC-02</acronym>
  <official_title>Androgen Deprivation Withdrawal Versus Maintenance and Intermittent Chemotherapy Versus Continuous in Prostate Cancer Patients With Castrate Resistant Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study includes the recruitment of patients with advanced prostate cancer resistant to&#xD;
      chemical castration This is a multicenter prospective trial randomized phase III&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes the recruitment of patients with advanced prostate cancer resistant to&#xD;
      chemical castration This is a multicenter prospective trial randomized phase III This study&#xD;
      design that includes a double randomizzzazione aims generally demonstrating non-inferiority&#xD;
      in terms of survival of the suspension dell'ormonoterapia versus the maintenance and / or&#xD;
      administration of intermittent versus continuous administration of chemotherapy in patients&#xD;
      with prostate cancer resistant to chemical castration I started to line chemotherapy with&#xD;
      Docetaxel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>six years</time_frame>
    <description>The primary aim of the study will be the demonstration of non inferiority in terms of overall survival of stopping androgen deprivation therapy (arm B) versus maintenance androgen deprivation therapy (arms A) and intermittent docetaxel therapy (arm AB1) versus continuous docetaxel therapy (arms AB2) up to ten cycles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>six years</time_frame>
    <description>Toxicity graded according to NCI Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>six years</time_frame>
    <description>Progression free survival measured according to Prostate Cancer Clinical Trials Working Group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>six years</time_frame>
    <description>Quality of life evaluated according to FACT-P questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>six years</time_frame>
    <description>Pain response evaluated by Mc-Gill Pain Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Analysis</measure>
    <time_frame>six years</time_frame>
    <description>A cost minimization analysis will be performed in order to find if there is a treatment strategy that may achieve the same outcome for least cost. The analysis will focus on the direct medical costs of each treatment, collected at patient level.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Advanced Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ten docetaxel cycles + maintenance androgen deprivation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>suspension arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten Docetaxel cycles + stop androgen deprivation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intermittent arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermittent Docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel + LH-RH analogues</intervention_name>
    <description>Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.&#xD;
In patients randomised to arms A up to 10 cycles of docetaxel will be planned in association to maintenance of LH-RH analogues administration.</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.&#xD;
In patients randomised to arms B up to 10 cycles of docetaxel will be planned, in association to stopping LH-RH analogues.</description>
    <arm_group_label>suspension arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Patients randomised in the arms AB1 (intermittent docetaxel) will suspend treatment after at least 4 cycles if their PSA level will be reduced &gt;50%. Docetaxel treatment will be resumed when the serum PSA will rise by &gt;50% from the lowest PSA level recorded and will be &gt;10 ng/mL or when there will be other evidence of disease progression. PSA progression must to be confirmed with a second assessment after 2 weeks before deciding to resume docetaxel administration.</description>
    <arm_group_label>intermittent arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuous Docetaxel</intervention_name>
    <description>Patients randomised in the arms AB2 (continuous docetaxel) will continue treatment up to ten cycles after even if their PSA level at 4 cycles will be reduced &gt;50% or will reach a level &lt;4 ng/mL.</description>
    <arm_group_label>Continuous arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuous Docetaxel</intervention_name>
    <description>Patients randomised in the arms AB1(intermittent docetaxel) will continue treatment up to ten cycles even if their PSA level after 4 cycles will be reduced &gt;50% or will reach a level &lt;4 ng/mL.</description>
    <arm_group_label>Continuous arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age over 18 years,&#xD;
&#xD;
          2. histologically documented adenocarcinoma of the prostate,&#xD;
&#xD;
          3. written informed consent to the study,&#xD;
&#xD;
          4. Castrate resistant metastatic prostate cancer in the presence of castrate levels of&#xD;
             testosterone (&lt;50 ng/ml) and eligible to docetaxel chemotherapy. The condition of&#xD;
             castrate resistant prostate cancer is the defined either as the documentation of a new&#xD;
             metastasis or PSA increase more than 50% or increase more than 25% from a lower PSA&#xD;
             value during previous hormone therapy in case of disease response or stabilization to&#xD;
             previous hormone therapy, respectively. Absolute PSA increase should be greater than 5&#xD;
             ng/ml,&#xD;
&#xD;
          5. an elevated PSA level must have been documented within 4 weeks of initiating docetaxel&#xD;
             chemotherapy,&#xD;
&#xD;
          6. more than 4 weeks since major surgery and fully recovered,&#xD;
&#xD;
          7. more than 4 weeks since any prior radiation with any toxicity attributable to&#xD;
             radiation resolved to grade 1 or less,&#xD;
&#xD;
          8. more than 8 weeks since the last dose of strontium or samarium,&#xD;
&#xD;
          9. ECOG Performance Status more than/equal to 2,&#xD;
&#xD;
         10. life expectancy &gt;6 months,&#xD;
&#xD;
         11. required initial laboratory values: absolute neutrophil count &gt; 1500/ul Platelets &gt;&#xD;
             100,000/ul., Hemoglobin &gt; 8.0 g/dl, Creatinine, SGOT, SGPT less than 2.0 X upper limit&#xD;
             of normal, Bilirubin less than/equal to upper limit of normal (ULN).&#xD;
&#xD;
         12. Appropriate patient compliance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with increased serum PSA levels with negative bone scan and CT scan.&#xD;
&#xD;
          2. Prior systemic chemotherapy for prostate cancer. Prior neoadjuvant or adjuvant&#xD;
             chemotherapy is permitted if there was no evidence of disease relapse within 12 months&#xD;
             of the last dose of chemotherapy,&#xD;
&#xD;
          3. Peripheral neuropathy &gt;grade 1,&#xD;
&#xD;
          4. myocardial infarction or significant change in anginal pattern within the last 6&#xD;
             months, symptomatic congestive heart failure (NYHA Class III or higher) or&#xD;
             uncontrolled cardiac arrhythmia,&#xD;
&#xD;
          5. patients with a history of severe hypersensitivity reaction to docetaxel or other&#xD;
             drugs formulated with polysorbate 80,&#xD;
&#xD;
          6. poorly controlled diabetes (fasting blood glucose &gt;250) despite optimization of&#xD;
             medical therapy, peptic ulcers or other contraindications to steroid therapy,&#xD;
&#xD;
          7. previous history of malignant disease with the exception of non melanoma skin cancer&#xD;
             curatively treated,&#xD;
&#xD;
          8. significant neurologic or psychiatric diseases preventing patients to give a valid&#xD;
             informed consent,&#xD;
&#xD;
          9. brain metastases,&#xD;
&#xD;
         10. prisoner status&#xD;
&#xD;
         11. because patients with immune deficiency are at increased risk of lethal infections&#xD;
             when treated with marrow-suppressive therapy, HIV-positive patients receiving&#xD;
             combination anti-retroviral therapy are excluded.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Berruti, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Oncology - Hospital San Luigi Gonzaga Orbassano (TO) - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Castagneto, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Oncology - Hospital San Giacomo of Novi Ligure (AL) Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcello Tucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncology - Hospital San Luigi Gonzaga of Orbassano (TO) - Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Davide Perroni</name>
      <address>
        <city>Saluzzo</city>
        <state>Cuneo</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roberto Faggiuolo</name>
      <address>
        <city>Alba</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franco Testore</name>
      <address>
        <city>Asti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mario Clerico</name>
      <address>
        <city>Biella</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrea Martoni</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massimo Aglietta</name>
      <address>
        <city>Candiolo (Torino)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberto Muzio</name>
      <address>
        <city>Casale Monferrato</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mario Botta</name>
      <address>
        <city>Casale Monferrato</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rodolfo Passalacqua</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marco Merlano</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luigi Toniolo</name>
      <address>
        <city>Garbagnate Milanese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sergio Bretti</name>
      <address>
        <city>Ivrea</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giovanni Ucci</name>
      <address>
        <city>Lodi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierfranco Conte</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carla Sculli</name>
      <address>
        <city>Mondovì</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscar Alabiso</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruno Castagneto</name>
      <address>
        <city>Novi Ligure</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giovanna Succu</name>
      <address>
        <city>Nuoro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfredo Berruti</name>
      <address>
        <city>Orbassano (Torino)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luigi Dogliotti</name>
      <address>
        <city>Orbassano (Torino)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luigi Cavanna</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giorgio Cruciani</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corrado Boni</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riccardo Ratti</name>
      <address>
        <city>Sanremo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Francesco Ferrau</name>
      <address>
        <city>Taormina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fausto Roila</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carlo Alberto Raucci</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guido Vietti Ramus</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Libero Ciuffreda</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gianpiero Fasola</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sergio Cozzi</name>
      <address>
        <city>Verbania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Domenico Amoroso</name>
      <address>
        <city>Viareggio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <last_update_submitted>October 19, 2010</last_update_submitted>
  <last_update_submitted_qc>October 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alfredo Berruti</name_title>
    <organization>Dipartimento Scienze Cliniche e Biologiche Università di Torino</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

